File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas

TitleAberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas
Authors
Issue Date2003
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJH
Citation
British Journal Of Haematology, 2003, v. 122 n. 1, p. 70-77 How to Cite?
AbstractNatural killer (NK) cell lymphomas lack suitable clonal markers for tumour cell detection, making the monitoring of minimal residual lymphoma difficult. Aberrant promoter CpG methylation occurs frequently in NK cell lymphomas. The objective of this study was to assess the potential of aberrant methylation as a surrogate tumour marker. Twenty-five primary tumours and 105 serial biopsies taken at various time points after treatment were examined using a methylation-specific polymerase chain reaction (MSP) for a panel of genes, comprising p73, p16, hMLH1, RARβ and p15, previously shown to be methylated in NK cell lymphomas. All samples underwent independent morphological examination, supplemented by immunostaining for CD56 and in-situ hybridization for Epstein-Barr-virus-encoded RNA. Primary tumours showed the frequent methylation of the genes p73 (92%), p16 (71%), hMLH1 (61%), RARβ (56%) and p15 (48%). MSP results in serial post-treatment biopsies were correlated with clinicopathological findings. Results were concordant in 89 follow-up samples (18 samples, histology positive/MSP positive; 71 samples, histology negative/MSP negative) and discordant in 16. Fifteen samples were histology negative/MSP positive, and tumour involvement was subsequently confirmed (positive re-biopsies or relapses at the same sites), indicating that MSP was more sensitive for minimal lymphoma detection. One sample was histology positive/MSP negative; a subsequent histological review and continuous clinical remission of the patient did not support tumour involvement. Our findings suggest that MSP for aberrantly methylated genes is a potentially valuable molecular marker for detecting either residual or relapsed disease in NK cell lymphoma patients.
Persistent Identifierhttp://hdl.handle.net/10722/162703
ISSN
2015 Impact Factor: 5.401
2015 SCImago Journal Rankings: 2.313
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSiu, LLPen_US
dc.contributor.authorChan, JKCen_US
dc.contributor.authorWong, KFen_US
dc.contributor.authorChoy, Cen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:22:31Z-
dc.date.available2012-09-05T05:22:31Z-
dc.date.issued2003en_US
dc.identifier.citationBritish Journal Of Haematology, 2003, v. 122 n. 1, p. 70-77en_US
dc.identifier.issn0007-1048en_US
dc.identifier.urihttp://hdl.handle.net/10722/162703-
dc.description.abstractNatural killer (NK) cell lymphomas lack suitable clonal markers for tumour cell detection, making the monitoring of minimal residual lymphoma difficult. Aberrant promoter CpG methylation occurs frequently in NK cell lymphomas. The objective of this study was to assess the potential of aberrant methylation as a surrogate tumour marker. Twenty-five primary tumours and 105 serial biopsies taken at various time points after treatment were examined using a methylation-specific polymerase chain reaction (MSP) for a panel of genes, comprising p73, p16, hMLH1, RARβ and p15, previously shown to be methylated in NK cell lymphomas. All samples underwent independent morphological examination, supplemented by immunostaining for CD56 and in-situ hybridization for Epstein-Barr-virus-encoded RNA. Primary tumours showed the frequent methylation of the genes p73 (92%), p16 (71%), hMLH1 (61%), RARβ (56%) and p15 (48%). MSP results in serial post-treatment biopsies were correlated with clinicopathological findings. Results were concordant in 89 follow-up samples (18 samples, histology positive/MSP positive; 71 samples, histology negative/MSP negative) and discordant in 16. Fifteen samples were histology negative/MSP positive, and tumour involvement was subsequently confirmed (positive re-biopsies or relapses at the same sites), indicating that MSP was more sensitive for minimal lymphoma detection. One sample was histology positive/MSP negative; a subsequent histological review and continuous clinical remission of the patient did not support tumour involvement. Our findings suggest that MSP for aberrantly methylated genes is a potentially valuable molecular marker for detecting either residual or relapsed disease in NK cell lymphoma patients.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJHen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.rightsBritish Journal of Haematology. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshCpg Islands - Geneticsen_US
dc.subject.meshDna Methylationen_US
dc.subject.meshDna, Neoplasm - Geneticsen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshKiller Cells, Naturalen_US
dc.subject.meshLymphoma, T-Cell - Diagnosis - Genetics - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm, Residualen_US
dc.subject.meshNose Neoplasms - Diagnosis - Genetics - Pathologyen_US
dc.subject.meshPolymerase Chain Reaction - Methodsen_US
dc.subject.meshPromoter Regions, Genetic - Geneticsen_US
dc.subject.meshTumor Markers, Biological - Geneticsen_US
dc.titleAberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1046/j.1365-2141.2003.04396.xen_US
dc.identifier.pmid12823347-
dc.identifier.scopuseid_2-s2.0-0038683899en_US
dc.identifier.hkuros77699-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0038683899&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume122en_US
dc.identifier.issue1en_US
dc.identifier.spage70en_US
dc.identifier.epage77en_US
dc.identifier.isiWOS:000183689800008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridSiu, LLP=35574705900en_US
dc.identifier.scopusauthoridChan, JKC=7403287069en_US
dc.identifier.scopusauthoridWong, KF=7404759860en_US
dc.identifier.scopusauthoridChoy, C=7202840937en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats